GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Cyclically Adjusted Price-to-FCF

Regen BioPharma (Regen BioPharma) Cyclically Adjusted Price-to-FCF : (As of Jun. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regen BioPharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Cyclically Adjusted Price-to-FCF Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regen BioPharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Cyclically Adjusted Price-to-FCF falls into.



Regen BioPharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regen BioPharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regen BioPharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.053/131.7762*131.7762
=-0.053

Current CPI (Mar. 2024) = 131.7762.

Regen BioPharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -28.829 100.560 -37.778
201409 -5.429 100.428 -7.124
201412 -5.629 99.070 -7.487
201503 -5.583 99.621 -7.385
201506 -5.243 100.684 -6.862
201509 -4.461 100.392 -5.856
201512 -5.120 99.792 -6.761
201603 -5.265 100.470 -6.906
201606 -4.779 101.688 -6.193
201609 -4.326 101.861 -5.596
201612 -5.250 101.863 -6.792
201703 -3.684 102.862 -4.720
201706 -4.533 103.349 -5.780
201709 -6.699 104.136 -8.477
201712 -6.600 104.011 -8.362
201803 -4.165 105.290 -5.213
201806 -0.794 106.317 -0.984
201809 -4.275 106.507 -5.289
201812 -1.064 105.998 -1.323
201903 -0.650 107.251 -0.799
201906 -1.175 108.070 -1.433
201909 -0.343 108.329 -0.417
201912 0.043 108.420 0.052
202003 -0.006 108.902 -0.007
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 -0.093 117.630 -0.104
202203 -0.039 121.301 -0.042
202206 -0.039 125.017 -0.041
202209 -0.029 125.227 -0.031
202212 -0.003 125.222 -0.003
202303 -0.032 127.348 -0.033
202306 -0.026 128.729 -0.027
202309 -0.006 129.860 -0.006
202312 -0.045 129.419 -0.046
202403 -0.053 131.776 -0.053

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma  (OTCPK:RGBP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regen BioPharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Industry
Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.